Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $3.90 million. The enterprise value is -$5.26 million.
Important Dates
The last earnings date was Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 9.06 million shares outstanding. The number of shares has increased by 377.09% in one year.
| Current Share Class | 9.06M |
| Shares Outstanding | 9.06M |
| Shares Change (YoY) | +377.09% |
| Shares Change (QoQ) | +142.70% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 6.86% |
| Float | 8.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.19 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.45% and return on invested capital (ROIC) is -76.74%.
| Return on Equity (ROE) | -154.45% |
| Return on Assets (ROA) | -42.18% |
| Return on Invested Capital (ROIC) | -76.74% |
| Return on Capital Employed (ROCE) | -112.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.54% in the last 52 weeks. The beta is 0.77, so TOVX's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -91.54% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 47.81 |
| Average Volume (20 Days) | 385,504 |
Short Selling Information
The latest short interest is 91,623, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 91,623 |
| Short Previous Month | 95,184 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 1.07% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.39M |
| Pretax Income | -20.35M |
| Net Income | -29.55M |
| EBITDA | -26.28M |
| EBIT | -26.39M |
| Earnings Per Share (EPS) | -$8.77 |
Full Income StatementBalance Sheet
The company has $12.12 million in cash and $2.89 million in debt, giving a net cash position of $9.23 million or $1.02 per share.
| Cash & Cash Equivalents | 12.12M |
| Total Debt | 2.89M |
| Net Cash | 9.23M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | 10.62M |
| Book Value Per Share | 1.17 |
| Working Capital | 2.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.07 million and capital expenditures -$16,000, giving a free cash flow of -$18.09 million.
| Operating Cash Flow | -18.07M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -18.09M |
| FCF Per Share | -$2.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |